Signal active
Organization
Contact Information
Overview
REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).
Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.
In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.
About
Biotechnology, Biopharma, Health Diagnostics
2006
1-10
Headquarters locations
Asia
Social
N/A
Profile Resume
REGiMMUNE headquartered in Asia, operates in the Biotechnology, Biopharma, Health Diagnostics sector. The company focuses on Biotechnology and has secured $5.6B in funding across 108 round(s). With a team of 1-10 employees, REGiMMUNE is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - REGiMMUNE, raised $6.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
9
9
0
$51.9M
Details
7
REGiMMUNE has raised a total of $51.9M in funding over 7 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2014 | Late Stage Venture | 9.2M | ||
2006 | Seed | 1.6M | ||
2007 | Early Stage Venture | 4.2M | ||
2008 | Early Stage Venture | 6.0M |
Investors
REGiMMUNE is funded by 32 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
REGiMMUNE | - | FUNDING ROUND - REGiMMUNE | 9.2M |
Nissay Capital | - | FUNDING ROUND - Nissay Capital | 9.2M |
REGiMMUNE | - | FUNDING ROUND - REGiMMUNE | 1.6M |
Ant Capital Partners | - | FUNDING ROUND - Ant Capital Partners | 1.6M |
Recent Activity
There is no recent news or activity for this profile.